Sai Parenteral’s IPO allotment probably at present: Examine standing, GMP, different particulars
Sai Parenteral’s IPO subscription standing
The mainboard challenge that closed on Friday, was subscribed 1.05 instances over a three-day bidding interval. It obtained over 78.80 lakh share bids towards 75,22,486 fairness shares out there for reserving.
The demand was primarily pushed by non-institutional buyers’ (NII) who subscribed the problem 2.36 instances. Certified Institutional Patrons (QIBs) subscribed the IPO 1.71 instances their quota, whereas Retail Particular person Traders (RIIs) hardly confirmed any curiosity, subscribing simply 12% shares of the out there quota.
Here is how one can examine the standing on BSE:
Step 1: Go to the BSE ‘Standing Software Examine’ web page https://www.bseindia.com/buyers/appli_check.aspx
Step 2: Choose Problem Sort: Fairness/Debt
Step 3: Put PAN/Software No. and enter checkbox ‘I am not a robotic’.Step 4: Submit ‘Search’
Its inventory is predicted to get listed on April 2.
About Sai Parenteral’s IPO
The corporate has set the value band at Rs 372– 392 per share and retail buyers could make purposes for no less than 1 lot which includes 38 fairness shares amounting to Rs 14,896.
The IPO’s recent challenge aggregates as much as Rs 285 crores whereas the OFS aggregates as much as Rs 123.79 crores which incorporates anchor investor portion of 31,28,485 fairness shares.
The corporate raised Rs 122.63 crore on Monday via 5 anchor buyers.
It has reserved 50% of the problem for certified institutional patrons (QIBs), as much as 35% for retail buyers and 15% for non-institutional buyers (NIIs).
Sai Parenteral’s IPO GMP
Shares of Sai Parenteral’s weren’t commanding any gray market premium (GMP) forward of the opening of the problem. This means a flat itemizing. The GMP is just an indicative value and will change as the problem progresses.
Sai Parenteral’s IPO internet proceeds
The gross proceeds from the problem will probably be to the tune of Rs 285 crore. The corporate will utilise Rs 110.8 crore in the direction of capability growth and upgradation of producing amenities, Rs 18 crore for institution of a brand new R&D Centre, Rs 14 crore in the direction of compensation of borrowings, and Rs 33 crore for its working capital necessities.
About Sai Parenteral’s
Sai Parenteral’s (SPL) is a diversified pharmaceutical formulations firm engaged within the enterprise of branded generic formulations and Contract Growth and Manufacturing Organisation (CDMO) merchandise & companies for the home and worldwide markets. The corporate’s portfolio consists of formulation merchandise, protecting each high-value and high-volume classes throughout therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, and so forth., with choices throughout dosage kinds reminiscent of injectables, tablets, capsules, liquid orals and ointments.
Sai Parenteral’s Financials
The corporate’s income from operations in H1FY26 stood at Rs 303 crore whereas its revenue after tax (PAT) stood at Rs 2 crore. For FY25, income stood at Rs 495 crore versus Rs 154 crore in FY24 and Rs 97 crore in FY23. The PAT stood at Rs 20 crore in FY25 versus Rs 8 crore in FY24 and Rs 4 crore in FY23.
Sai Parenteral’s IPO lead managers
The Guide Operating Lead Managers (BRLMs) is Arihant Capital Markets Ltd whereas the registrar to the problem is Bigshare Providers Pvt Ltd.
(Disclaimer: The suggestions, ideas, views, and opinions given by the specialists are their very own. These don’t symbolize the views of The Financial Instances.)
Leave a Reply